新型冠状病毒疫苗研究最新进展

doi:10.19871/j.cnki.xfcrbzz.2020.04.012

摘要/Abstract

摘要： 新型冠状病毒肺炎(COVID-19)在世界范围的大流行,引发了全球医疗资源危机。该疾病传染性强,传播范围广,而临床尚无有效的疫苗进行预防。鉴于疫情防控的紧迫性,开发安全有效的新型冠状病毒疫苗迫在眉睫。本文首先就保护性抗体抗病毒的免疫机制,分别从冠状病毒诱导不同类型抗体的产生及保护性抗体如何发挥抗病毒效应等方面进行阐述。其次,以严重急性呼吸综合征冠状病毒 (SARS-CoV)、中东呼吸综合征冠状病毒(MERS-CoV)2种下呼吸道感染的冠状病毒为例,总结新型冠状病毒疫苗研发如何借鉴SARS-CoV和MERS-CoV疫苗研究背景选择疫苗开发的最优抗原,并从SARS-CoV、MERS-CoV疫苗安全性和有效性评价中探讨新型冠状病毒疫苗开发的潜在问题。接着,对临床在研新型冠状病毒疫苗最新进展按疫苗类型分类阐述。目前,虽然从临床试验完成到大规模生产应用的挑战仍然较多,但是快速研发疫苗进展迅速,有望短期内获得安全有效的疫苗。最后,疫苗策略应结合公共卫生策略如保持物理距离、早期发现、自我隔离和暴发控制等措施联合防疫。

关键词: 冠状病毒, 新型冠状病毒肺炎, 中和性抗体, 疫苗, 安全性

Abstract: The ongoing pandemic of coronavirus disease-2019 (COVID-19) has led to severe global health burden.However,no effective vaccine has been developed yet.The development of a safe and effective COVID-19 vaccine is urgent for the disease control.In the present review,we firstly described the mechanisms of neutralizing antibodies-mediated immune responses.We elucidated different neutralizing antibodies which are induced by Coronavirus vaccines,and described how they induce anti-viral response.Secondly,we took the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV) as examples,and summarized how the new coronavirus (SARS-CoV2) vaccine development can learn from SARS and MERS vaccine research in selecting antigens.Furthermore,we discussed the potential problems for COVID-19 vaccine development about evaluating the safety and effectiveness of SARS-CoV and MERS-CoV vaccines.Next,we summarized the current clinical trials of COVID-19 vaccines.Although there are challenges from the clinical trials to large-scale production and application,the development of vaccines is so rapidly nowadays,and it’s potential to get safe and effective vaccines in a short time.At last,the vaccines strategy should be combined with public health strategies such as keeping physical distance,early detection,self-isolation and outbreak control to against COVID-19.

Key words: Coronavirus, Coronavirus disease-2019, Neutralizing antibodies, Vaccines, Safety

李倩, 卢洪洲. 新型冠状病毒疫苗研究最新进展[J]. 新发传染病电子杂志, 2020, 5(4): 268-273.

Li Qian, Lu Hongzhou. Progress on coronavirus disease2019vaccines: current status[J]. Electronic Journal of Emerging Infectious Diseases, 2020, 5(4): 268-273.

参考文献

[1] World Health Organization.WHO Coronavirus Disease (COVID-19) Dashboard[EB/OL].[2020-11-18].https://www.covid19.who.int.
[2] World Health Organization.WHO:Draft landscape of COVID-19 candidate vaccines[EB/OL].[2020-11-18].https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
[3] World Health Organization.WHO target product profiles for COVID-19 vaccines[EB/OL].https://www.who.int/publications/m/item/who-target-product-profiles-for-covid-19-vaccines.
[4] Poland G,Ovsyannikova I,Crooke S,et al.ARS-CoV-2 Vaccine Development:Current Status[J].Mayo Clin Proc,2020,95(10):2172-2188.
[5] Su S,Du L,Jiang S.Learning from the past:development of safe and effective COVID-19 vaccines[J].Nat Rev Microbiol,2020,10:1-9.
[7] Chiu SS,Chan KH,Chu KW,et al.Human coronavirus NL63 infection and other coronavirus infections in children hospitalized with acute respiratory disease in Hong Kong,China[J].Clin Infect Dis,2005,40(12):1721-1729
[7] Gorse GJ,O’Connor TZ,Hall SL,et al.Human coronavirus and acute respiratory illness in older adults with chronic obstructive pulmonary disease[J].JInfect Dis,2009,199(6):847-857.
[8] Jean A,Quach C,Yung A,et al.Severity and outcome associated with human coronavirus OC43 infections among children[J].Pediatr Infect Dis J,2013,32(4):325-329
[9] Jevšnik M,Uršic T,Zigon N,et al.Coronavirus infections in hospitalized pediatric patients with acute respiratory tract disease[J].BMC Infect Dis,2012,12:365.
[10] Lu G,Wang Q,Gao GF.Bat-to-human:spike features determining ‘host jump’of coronaviruses SARS-CoV,MERS-CoV,and beyond[J].Trends Microbiol,2015,23(8):468-478
[11] Liu W,Fontanet A,Zhang PH,et al.Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome[J].J Infect Dis,2006,193(6):792-795
[12] Liu WJ,Zhao M,Liu K,et al.T-cell immunity of SARS-CoV:Implications for vaccine development against MERS-CoV[J].Antiviral Res,2017,137:82-92
[13] Zhou P,Yang X,Wang X,et al.A pneumonia outbreak associated with a new coronavirus of probable bat origin[J].Nature,2020,579(7798):270-273
[14] Christoph K,Matthias Zehner,Timm Weber,et al.Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients[J].Cell,2020,182(4):843-854
[15] Ann MA,Katja F,Michael AS,et al.A perspective on potential antibody-dependent enhancement of SARS-CoV-2[J].Nature,2020,584(7821):353-363.
[16] Braun J,Loyal L,Frentsch M,et al.SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19[J].Nature,2020,587(7833):270-274.
[17] Grifoni A,Weiskopf D,Ramirez SI,et al.Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID19 disease and unexposed individuals[J].Cell,2020,1 81(7):1489-1501.e15.
[18] Juno JA,Tan H-X,Lee WS,et al.Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19[J].Nat Med,2020,26(9):1428-1434.
[19] Lu R,Zhao X,Li J,et al.Genomic characterisation and epidemiology of 2019 novel coronavirus:implications for virus origins and receptor binding[J].Lancet,2020,395(10224):565-574.
[20] Verdecchia P,Cavallini C,Spanevello A,et al.The pivotal link between ACE2 deficiency and SARS-CoV-2 infection[J].Eur J Intern Med,2020,76:14-20.
[21] Herrera NG,Morano NC,Celikgil A,et al.Characterization of the SARS-CoV-2 S protein:biophysical,biochemical,structural,and antigenic analysis[J].bioRxiv,2020,06.14.doi:10.1101/2020.06.14.150607.Preprint.
[22] Hoffmann M,Kleine-Weber H,Schroeder S,et al.SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor[J].Cell,2020,181(2):271-.280.e8
[23] Rottier PJM.The Coronavirus Membrane Glycoprotein[M].Berlin:Springer,1995:115-139.
[24] Hoffmann M,Kleine-Weber H,Pöhlmann S.A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells[J].Mol Cell,2020,78:779-784.
[25] Du L,He Y,Zhou Y,et al.The spike protein of SARS-CoV--a target for vaccine and therapeutic development[J].Nat Rev Microbiol.2009,7(3):226-236.
[26] Tseng C,Sbrana E,Iwata-Yoshikawa,et al.Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus[J].PLoS One,2012,7(4):e35421.
[27] Woo P,Lau S,Wong B,et al.Longitudinal profile of immunoglobulin G (IgG),IgM,and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus[J].Clin Diagn Lab Immunol,2004,11:665-668.
[28] Siu YL,Teoh KT,Lo J,et al.The M,E,and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly,trafficking,and release of virus-like particles[J].J Virol,2008,82(22):11318-11330.
[29] Yang J,Wang W,Chen Z,et al.A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity[J].Nature,2020,586(7830):572-577.
[30] Wang C,Zheng X,Gai W,et al.Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific humoral and cellular immune response in mice[J].Antiviral Res,2017,140:55-61.
[31] Roberts A,Lamirande EW,Vogel L,et al.Immunogenicity and protective efficacy in mice and hamsters of a bPropiolactone inactivated whole virus SARS-CoV vaccine[J].Viral Immunol,2010,23(5):211-219.
[32] Agrawal A,Tao X,Algaissi A,et al.Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus[J].Hum Vaccin Immunother,2016,12(9):2351-2356.
[33] Deming T,Sheahan M,Heise B,et al.Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants[J].PLoS Med,2006,3(12):e525.
[34] Yasui F,Kai C,Kitabatake M,et al.Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV[J].J Immunol,2008,181(9):6337-6348.
[35] Chen W,Tao X,Agrawal A,et al.Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with alum induces protective immunity and reduces immune enhancement[J].bioRxiv,2020,05.15.098079.doi:10.1101/2020.05.15.098079.Preprint.
[36] Lee WS,Wheatley AK,Kent SJ,et al.Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies[J].Nat Microbiol,2020,5(10):1185-1191.
[37] Fedechkin S,George N,Castrejon A,et al.Conformational flexibility in respiratory syncytial virus G neutralizing epitopes[J].J Virol,2020,94(6):e01879-1919.
[38] Capeding MR,Tran N,Hadinegoro S,et al.Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia:a phase 3,randomised,observer-masked,placebo-controlled trial[J].Lancet,2014,384:1358-1365.
[39] Lin J,Huang N,Li J,et al.Cross-reactive antibodies against dust mite-derived enolase induce neutrophilic airway inflammation[J].Eur Respir J,2020,13:1902375.Online ahead of print.
[40] Cao X.COVID-19:immunopathology and its implications for therapy[J].Nat Rev Immunol,2020,20(5):269-270.
[41] Lambert P,Ambrosino D,Andersen S,et al.Consensus summary report for CEPI/BC March 12-13,2020 meeting:assessment of risk of disease enhancement with COVID-19 vaccines[J].Vaccine,2020,38(31):4783-4791.
[42] Moore JP,Klasse PJ.SARS-CoV-2 vaccines:‘warp speed' needs mind melds not warped minds[J].JVirol,2020,94(17):e01083-20.
[43] Du L,Zhao G,He Y,et al.Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model[J].Vaccine,2007,25:2832-2838.
[44] FDA.Recommendations for Investigational COVID-19 Convalescent Plasma[EB/OL].[2020-08-23].https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma
[45] Seow J,Doores K.Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection[J].Nature Microbiology,2020,5:1598-1607.
[46] Zhang YJ,Zeng G,Pan H,et al.Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years:report of the randomized,double-blind,and placebo-controlled phase 2 clinical trial[J].med Rxiv,2020,8:1-22.
[47] Xia S,Duan K,Zhang Y,et al.Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes:interim analysis of 2 randomized clinical trials[J].JAMA,2020,324(10):951-960.
[48] Zhu F,Guan X,Li Y,et al.Immunogenicity and safety of a recombinant adenovirus type-5- vectored COVID-19 vaccine in healthy adults aged 18 years or older:a randomised,double-blind,placebo-controlled,phase 2 trial[J].Lancet,2020,396:479-488.
[49] Folegatti P,Ewer K,Aley P,et al.Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2:a preliminary report of a phase 1/2,single-blind,randomised controlled trial[J].Lancet,2020,396(10249):467-478.
[50] Logunov D,Dolzhikova I,Zubkova O,et al.Safety and immunogenicity of an rAd26 and rAd5 vectorbased heterologous prime-boost COVID-19 vaccine in two formulations:two open,non-randomised phase 1/2 studies from Russia[J].Lancet.2020,396(10255):887-897.
[51] Mercado N,Zahn R,Wegmann F,et al.Single-shot Ad26 vaccine protects against SARS-CoV-2 I rhesus macaques[J].Nature,2020,586(7830):583-588.
[52] Mulligan M,Lyke K,Kitchin N,et al.Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults[J].Nature,2020,586(7830):589-593.
[53] Jackson L,Anderson E,Rouphael N,et al.An mRNA Vaccine against SARS-CoV-2—preliminary report[J].N EngJ Med,2020,383(20):1920-1931.
[54] 郝鹏飞,许汪,杜寿文,等.冠状病毒起源、受体及新型冠状病毒检测与疫苗最新研究进展[J/CD].新发传染病电子杂志,2020,5(2):74-78.

[1]	吕秋莹, 梅树江, 张仁利, 吴永胜, 何建凡, 李媛, 彭博, 张振, 逯建华, 高玮, 房师松, 王敬忠, 温莹, 程聪, 邹旋, 夏俊杰, 彭朝琼, 冯铁建. 新型冠状病毒肺炎精准防控体系构建与效果评价[J]. 新发传染病电子杂志, 2020, 5(4): 229-233.
[2]	宋玉燕, 黄长先, 周璐, 张英, 张安, 詹柱, 李群堂, 邱敏. 中西医结合疗法治疗31例重型新型冠状病毒肺炎临床疗效分析[J]. 新发传染病电子杂志, 2020, 5(4): 239-242.
[3]	任坦坦, 陆普选, 邓国防, 付亮, 张培泽. 2020 WHO全球结核报告:全球与中国关键数据分析[J]. 新发传染病电子杂志, 2020, 5(4): 280-284.
[4]	林绿, 刘夏, 吴念宁, 邹俊, 蓝健, 黄金萍, 陈薪宇, 黄妹青. 血清心肌损伤指标变化与新型冠状病毒肺炎重症风险的相关性研究[J]. 新发传染病电子杂志, 2020, 5(3): 159-164.
[5]	朱芸仙, 刘静, 任砚, 吴敏昱, 任荣, 朱怡, 姚文妍, 李敏. 新型冠状病毒肺炎核酸检测阳转阴前后CT影像对比[J]. 新发传染病电子杂志, 2020, 5(3): 183-187.
[6]	吴锋耀, 蒙婞婞, 韦彩云, 刘冬梅. 传染病医院新型冠状病毒肺炎疫情防控与职业健康长效机制建设[J]. 新发传染病电子杂志, 2020, 5(3): 198-202.
[7]	. 新型冠状病毒肺炎放射检查方案与感染防控专家共识（试行第一版）[J]. 新发传染病电子杂志, 2020, 5(2): 65-73.
[8]	郝鹏飞, 许汪, 杜寿文, 金宁一, 吴诗品, 李昌, 李体远. 冠状病毒起源、受体及新型冠状病毒检测与疫苗最新研究进展[J]. 新发传染病电子杂志, 2020, 5(2): 74-78.
[9]	卢亦波, 周静如, 莫移美, 宋树林, 刘铁军. 31例新型冠状病毒肺炎临床及CT影像表现初步观察[J]. 新发传染病电子杂志, 2020, 5(2): 79-82.
[10]	宋璐, 曾莹婷, 龚晓明, 张笑春, 鲁植艳. 新型冠状病毒肺炎影像表现及鉴别诊断[J]. 新发传染病电子杂志, 2020, 5(2): 83-86.
[11]	江芮, 刘晋新, 张烈光, 黄德扬, 陈碧华, 瞿静, 林琳, 余成成, 凌洲焜. 8组家族聚集性发病的新型冠状病毒肺炎胸部CT表现及转归[J]. 新发传染病电子杂志, 2020, 5(2): 87-90.
[12]	洪玲玲, 徐晓婧, 付小义. 一起家族聚集性新型冠状病毒肺炎病例的心理干预总结分析[J]. 新发传染病电子杂志, 2020, 5(2): 91-94.
[13]	郑秋婷, 卢亦波, 谭理连, 陆普选. 新型冠状病毒肺炎临床及影像学研究进展[J]. 新发传染病电子杂志, 2020, 5(2): 140-144.
[14]	王然, 高娜, 安静. Ⅱ型登革病毒DNA疫苗在小鼠体内免疫保护作用与性别相关性的研究[J]. 新发传染病电子杂志, 2018, 3(2): 98-101.
[15]	王玉臣, 陈福增, 黄滢睿, 张鹭, 刘军. 结核分枝杆菌PE31抗原的免疫原性及保护效果研究[J]. 新发传染病电子杂志, 2017, 2(3): 155-159.